论文部分内容阅读
目的探讨肝癌特异性ＧＧＴ的动态变化及其定量分析的临床价值。方法以化学致癌剂２－ＦＡＡ（００５％）制备鼠肝癌模型，观察肝癌ＧＧＴ的产生及其肝组织内分布，并对不同肝病患者血清肝癌特异性ＧＧＴ区带（ＨＳＢ）进行定量分析研究。结果在实验性鼠的诱癌过程中，鼠肝脏癌变组织中ＧＧＴ大量表达，出现早并具有胎肝ＧＧＴ的特点；人血清中ＨＳＢ的定量检测发现：肝癌组明显高于其他肝病组，肝外肿瘤及正常对照组（Ｐ＜０００１）；ＨＳＢ在小肝癌中的阳性率为７５％，在ＡＦＰ阴性肝癌中为７８３％。结论研究资料提示ＨＳＢ的定量检测其临床价值优于ＨＳＢ的定性分析，且有助于小肝癌和ＡＦＰ阴性肝癌的早期诊断。
Objective To investigate the dynamic changes of liver cancer-specific GGT and its clinical value. Methods A rat hepatocellular carcinoma model was prepared with 2-FAA (005%) as a chemical carcinogen. The GGT production and intrahepatic tissue distribution in hepatocellular carcinoma were observed. Quantitative analysis of serum GGT-specific GGT bands in different liver diseases was performed. . RESULTS: In the process of murine carcinogenesis, GGT was abundantly expressed in rat liver cancerous tissue and appeared early and had characteristics of fetal liver GGT. Quantitative detection of HSB in human serum revealed that liver cancer group was significantly higher than other liver disease groups. Tumor and normal control group (P<0001); HSB positive rate in small HCC was 75%, and in AFP-negative HCC was 783%. Conclusions Research data suggest that the clinical value of quantitative detection of HSB is better than the qualitative analysis of HSB, and it is helpful for the early diagnosis of small hepatocellular carcinoma and AFP-negative liver cancer.